{"id":4713,"date":"2026-05-30T07:58:08","date_gmt":"2026-05-30T07:58:08","guid":{"rendered":"https:\/\/www.insuracarelife.com\/blog\/health-care-week-in-review-tri-agencies-release-federal-independent-dispute-resolution-idr-operations-final-rule-cms-updates-increasing-organ-transplant-access-model-alston-bird\/"},"modified":"2026-05-30T07:58:08","modified_gmt":"2026-05-30T07:58:08","slug":"health-care-week-in-review-tri-agencies-release-federal-independent-dispute-resolution-idr-operations-final-rule-cms-updates-increasing-organ-transplant-access-model-alston-bird","status":"publish","type":"post","link":"https:\/\/www.insuracarelife.com\/blog\/health-care-week-in-review-tri-agencies-release-federal-independent-dispute-resolution-idr-operations-final-rule-cms-updates-increasing-organ-transplant-access-model-alston-bird\/","title":{"rendered":"Health Care Week in Review | Tri-Agencies Release Federal Independent Dispute Resolution (IDR) Operations Final Rule; CMS Updates Increasing Organ Transplant Access Model | Alston & Bird"},"content":{"rendered":"
\n

Below is Alston & Bird\u2019s Health Care Week in Review<\/em>, which provides a synopsis of the latest news in health care regulations, notices, and guidance; federal legislation and congressional committee action; reports, studies, and analyses; and other health policy news.<\/p>\n

\n

Highlight of the Week<\/strong><\/p>\n

This week, the Tri-Agencies finalized updated standards for payers, providers, and certified IDR entities related to the Federal IDR process under the No Surprises Act and CMS revised the Increasing Organ Transplant Access (IOTA) Model to align with administration priorities.<\/p>\n

Regulations, Notices & Guidance<\/h2>\n
    \n
  • On May 27, 2026, the Food and Drug Administration (FDA) released a notice entitled, Request for Information: AI-Enabled Optimization of Early-Phase Clinical Trials Pilot Program<\/em>. FDA is extending the comment period for the notice entitled \u201cAI-Enabled Optimization of Early-Phase Clinical Trials Pilot Program; Request for Information\u201d that appeared in the Federal Register of April 29, 2026. In the notice, FDA requested comments to solicit input on a proposed pilot program to assess how artificial intelligence (AI)-enabled technologies can improve efficiency, speed, and quality of decision-making in early phase clinical trials. FDA is taking this action in response to a request for an extension to allow interested persons additional time to submit comments.<\/li>\n
  • On May 27, 2026, the Centers for Disease Control and Prevention (CDC) released a notice entitled, Amended Order Under Sections 362 and 365 of the Public Health Service Act Suspending Introduction of Certain Persons From Countries Where a Communicable Disease Exists<\/em>. The Assistant Secretary for Health issued the Amended Order prohibiting the introduction of certain persons who have departed from, or were otherwise present within, specified countries during the last 21 days. This Amended Order reflects recent updates to 42 CFR 71.40(f), which no longer provides an exemption for lawful permanent residents under the foreign quarantine regulations. The Amended Order is effective for a period of 30 days.<\/li>\n
  • On May 28, 2026, the Departments of Health and Human Services (HHS), Labor, and Treasury (Tri-Agencies) and the Office of Personnel Management released final rules entitled, Federal Independent Dispute Resolution Operations<\/em>. These final rules finalize new requirements relating to the disclosure of information that group health plans and health insurance issuers offering group or individual health insurance coverage must include along with the initial payment or notice of denial of payment for certain items and services subject to the surprise billing protections in the No Surprises Act <\/em>(NSA). These final rules also require plans and issuers to communicate information by using claim adjustment reason codes (CARCs) and remittance advice remark codes (RARCs), as specified in guidance, when providing any paper or electronic remittance advice (ERA) to an entity that does not have a contractual relationship with the plan or issuer. These final rules also finalize amendments to certain requirements related to the open negotiation period preceding the Federal Independent Dispute Resolution (IDR) process, the initiation of the Federal IDR process, the Federal IDR dispute eligibility review process, and the payment and collection of administrative fees and certified IDR entity fees. Further, these final rules finalize the definition of bundled payment arrangements, amend requirements related to batched items and services, and amend the rules for extensions of timeframes due to extenuating circumstances. Additionally, these final rules finalize provisions that require plans and issuers to register in the Federal IDR portal.<\/li>\n
  • On May 28, 2026, FDA released guidance entitled, Bioequivalence Studies With Pharmacokinetic Endpoints for Drugs Submitted Under an Abbreviated New Drug Application<\/em>. This guidance provides recommendations to applicants planning to submit bioequivalence (BE) information in abbreviated new drug applications (ANDAs) as well as amendments and supplements to ANDAs. In addition, this guidance describes how to meet the BE requirements set forth in the Federal Food, Drug, and Cosmetic Act<\/em> (FD&C Act) and FDA regulations. This guidance is applicable to immediate-release and modified-release oral dosage forms. It is also applicable to non-orally administered drug products for which reliance on systemic exposure measures is suitable for establishing BE (e.g., transdermal delivery systems and certain rectal and nasal drug products). This guidance will also be useful to applicants planning BE studies that are intended to be conducted during the postapproval period, for changes to a drug product approved under an ANDA.<\/li>\n
  • On May 28, 2026, FDA released guidance entitled, Statistical Approaches to Establishing Bioequivalence<\/em>. This guidance provides recommendations on how to meet provisions of part 320 (21 CFR part 320) for all drug products. Part 320 sets forth requirements for (1) submitting bioavailability (BA) and BE data in investigational new drug applications (INDs), new drug applications (NDAs), and ANDAs, as well as amendments and supplements to these applications; (2) the definitions of BA and BE; and (3) the types of in vitro and in vivo studies that are appropriate to measure BA and establish BE. This guidance replaces prior FDA guidance for industry of the same name issued in February 2001 (2001 guidance).<\/li>\n
  • On May 28, 2026, FDA released guidance entitled, Content of Human Factors Information in Medical Device Marketing Submissions; Guidance for Industry and Food and Drug Administration Staff<\/em>. This guidance provides a risk-based framework to guide manufacturers and FDA staff on the human factors information that should be included in a marketing submission to the Center for Devices and Radiological Health (CDRH) to facilitate the efficiency of the FDA review process.<\/li>\n
  • On May 28, 2026, FDA released a notice entitled, Charter Amendments, Establishments, Renewals and Terminations: Psychopharmacologic Drugs Advisory Committee<\/em>. FDA is announcing the renewal of the Psychopharmacologic Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Psychopharmacologic Drugs Advisory Committee for an additional two years beyond the charter expiration date. The new charter will be in effect until the new expiration date of June 4, 2028.<\/li>\n
  • On May 28, 2026, CMS released guidance entitled, Key Dates for Calendar Year 2026:<\/em> Qualified Health Plan (QHP) Data Submission and Certification; Rate Review; Form Review; and Risk Adjustment<\/em>. This guidance summarizes key dates for calendar year (CY) 2026 regarding specified activities and policies that are outlined in other documents. These dates apply to qualified health plans (QHPs) in states with Exchanges that use the HealthCare.gov platform. This includes QHPs in Federally-facilitated Exchanges (including those where the state performs plan management functions) and State-based Exchanges on the HealthCare.gov platform.<\/li>\n
  • On May 28, 2026, HHS released a final rule entitled, Medicare Program; Alternative Payment Model Updates and the Increasing Organ Transplant Access (IOTA) Model<\/em>. This final rule finalizes updates and revisions to the Increasing Organ Transplant Access (IOTA) Model for Performance Year (PY) 2, which will begin on July 1, 2026, and future PYs in response to improvement opportunities that arose during implementation of the 2024 Medicare Program; Alternative Payment Model Updates and the Increasing Organ Transplant Access (IOTA) Model<\/em> final rule and to better align the model with new administration priorities. The IOTA Model is aimed at kidney transplant hospitals with the goal of increasing the number of kidney transplants, improving quality of care, and improving patient experience during the transplant process.<\/li>\n<\/ul>\n

    Event Notices<\/h3>\n

    Please note that two asterisks (**) preceding the item indicate a new event.<\/p>\n

      \n
    • June 1-2, 2026:<\/strong> The National Institutes of Health (NIH) announced a meeting of the Fogarty International Center Advisory Board. This is a hybrid meeting with some sessions open to the public.<\/li>\n
    • June 2, 2026:<\/strong> NIH announced a meeting of the National Arthritis and Musculoskeletal and Skin Diseases Advisory Council. This is a hybrid meeting with some sessions open to the public.<\/li>\n
    • June 2, 2026:<\/strong> CMS announced the first biannual Healthcare Common Procedure Coding System (HCPCS) Level II public meeting of 2026. This is a hybrid meeting open to the public.<\/li>\n
    • June 4, 2026: <\/strong>FDA announced that a public hearing related to the Commissioner\u2019s National Priority Voucher (CNPV) Pilot Program will be rescheduled to June 4, 2026. This is a hybrid meeting open to the public.<\/li>\n
    • June 5, 2026:<\/strong> NIH announced a meeting of the National Institute of Child Health and Human Development. This is a hybrid meeting with some sessions open to the public.<\/li>\n
    • June 5, 2026:<\/strong> NIH announced a meeting of the National Advisory Eye Council. This is a virtual meeting with some sessions open to the public.<\/li>\n
    • June 5, 2026: <\/strong>CDC announced a meeting of the Subcommittee on Procedure Reviews of the Advisory Board on Radiation and Worker Health (ABRWH). This is a virtual meeting open to the public.<\/li>\n
    • June 8, 2026:<\/strong> NIH announced a meeting of the President\u2019s Cancer Panel. This is an in-person meeting open to the public.<\/li>\n
    • June 8-9, 2026: <\/strong>FDA announced a public workshop entitled, Fiscal Year 2026 Generic Drug Science and Research Initiatives Workshop<\/em>. This is a hybrid meeting open to the public.<\/li>\n
    • June 9, 2026:<\/strong> NIH announced a meeting of the National Heart, Lung, and Blood Institute. This is an in-person meeting open to the public.<\/li>\n
    • June 10, 2026:<\/strong> CMS announced a public meeting regarding new and reconsidered clinical diagnostic laboratory test codes for the Clinical Laboratory Fee Schedule (CLFS) for CY 2027.<\/li>\n
    • June 10-11, 2026:<\/strong> NIH announced a meeting of the National Institute of Diabetes and Digestive and Kidney Diseases. This is a hybrid meeting with some sessions open to the public.<\/li>\n
    • June 12, 2026:<\/strong> NIH announced a meeting of the NIH Clinical Center Research Hospital Board. This is a hybrid meeting open to the public.<\/li>\n
    • June 15, 2026:<\/strong> NIH announced a meeting of the National Institute of Environmental Health Sciences (NIEHS) Board of Scientific Counselors. This is a hybrid meeting with some sessions open to the public.<\/li>\n
    • **June 15, 2026:<\/strong> FDA announced a meeting entitled, Challenges and Solutions in Lot-Level Food Traceability<\/em>. This is a virtual meeting open to the public.<\/li>\n
    • June 15-16, 2026: <\/strong>HHS announced a meeting of the Physician-Focused Payment Model Technical Advisory Committee (PTAC). This is a hybrid meeting open to the public.<\/li>\n
    • June 15-16, 2026: <\/strong>NIH announced a meeting of the National Institute of Biomedical Imaging and Bioengineering Board of Scientific Counselors. This is an in-person meeting with some sessions open to the public.<\/li>\n
    • June 16, 2026:<\/strong> NIH announced a meeting of the Interagency Pain Research Coordinating Committee. This is a virtual meeting open to the public.<\/li>\n
    • June 18, 2026: <\/strong>CMS announced a meeting of the ABRWH. This is a virtual meeting open to the public.<\/li>\n
    • June 18, 2026:<\/strong> FDA announced a meeting of the Vaccines and Related Biological Products Advisory Committee. This is a virtual meeting open to the public.<\/li>\n
    • June 22, 2026: <\/strong>NIH announced a meeting of the National Institute of Allergy and Infectious Diseases (NIAID). This is a virtual meeting with some sessions open to the public.<\/li>\n
    • **June 22, 2026:<\/strong> NIH announced a meeting of the National Institute of Mental Health. This is a virtual meeting with some sessions open to the public.<\/li>\n
    • June 23, 2026:<\/strong> FDA announced a meeting entitled, Financial Transparency and Efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments<\/em>. This is a hybrid meeting open to the public.<\/li>\n
    • June 24, 2026:<\/strong> NIH announced a meeting of the Diabetes Mellitus Interagency Coordinating Committee (DMICC). This is a virtual meeting open to the public.<\/li>\n
    • June 24, 2026:<\/strong> NIH announced a meeting of the NIEHS. This is a virtual meeting with some sessions open to the public.<\/li>\n
    • June 25, 2026:<\/strong> NIH announced a meeting of the Office of AIDS Research Advisory Council. This is a hybrid meeting open to the public.<\/li>\n
    • June 29, 2026:<\/strong> NIH announced a meeting of the National Cancer Advisory Board. This is a hybrid meeting with some sessions open to the public.<\/li>\n
    • June 29, 2026:<\/strong> NIH announced a meeting of the National Advisory Council for Complementary and Integrative Health. This is a virtual meeting with some sessions open to the public.<\/li>\n
    • June 29, 2026:<\/strong> NIH announced a meeting of the Advisory Council on Parkinson’s Research, Care, and Services (ACPRCS). This is a virtual meeting open to the public.<\/li>\n
    • June 30, 2026:<\/strong> NIH announced a meeting of the National Institute of Neurological Disorders and Stroke. This is a hybrid meeting with some sessions open to the public.<\/li>\n
    • July 6-7, 2026:<\/strong> NIH announced a meeting of the National Cancer Institute (NCI). This is a virtual meeting with some sessions open to the public.<\/li>\n
    • July 8, 2026:<\/strong> NIH announced a meeting of the National Advisory Child Health and Human Development Council. This is a hybrid meeting with some sessions open to the public.<\/li>\n
    • July 14-15, 2026:<\/strong> CMS announced a meeting of the Medicare Advisory Panel on Clinical Diagnostic Laboratory Tests. This is a hybrid meeting open to the public.<\/li>\n
    • July 15, 2026:<\/strong> NIH announced a meeting of the NCI Clinical Trials and Translational Research Advisory Committee. This is a virtual meeting open to the public.<\/li>\n
    • July 23-24,<\/strong> 2026:<\/strong> FDA announced a meeting of the Pharmacy Compounding Advisory Committee. This is a hybrid meeting open to the public.<\/li>\n
    • August 6, 2026:<\/strong> NIH announced a meeting of the National Heart, Lung, and Blood Institute. This is a hybrid meeting open to the public.<\/li>\n
    • **August 25, 2026: <\/strong>FDA announced a meeting entitled, Patient-Focused Drug Development for Nonhealing Chronic Wounds<\/em>. This is a hybrid meeting open to the public.<\/li>\n
    • September 10-11, 2026:<\/strong> NIH announced a meeting of the Fogarty International Center Advisory Board. This is a hybrid meeting with some sessions open to the public.<\/li>\n
    • September 14-15, 2026: <\/strong>HHS announced a meeting of PTAC. This is a hybrid meeting open to the public.<\/li>\n
    • September 15-16, 2026:<\/strong> CMS announced a meeting of the Medicare Advisory Panel on Clinical Diagnostic Laboratory Tests. This is a virtual meeting open to the public.<\/li>\n
    • September 15-16, 2026: <\/strong>NIH announced a meeting of the National Advisory Council on Aging. This is a hybrid meeting with some sessions open to the public.<\/li>\n
    • September 24, 2026: <\/strong>The Office of the National Coordinator for Health IT (ONC) <\/strong>announced a meeting of the Health Information Technology Advisory Committee. This is a virtual meeting open to the public.<\/li>\n
    • November 5, 2026: <\/strong>ONC announced a meeting of the Health Information Technology Advisory Committee. This is a virtual meeting open to the public.<\/li>\n
    • December 7-8, 2026: <\/strong>NIH announced a meeting of NICHD. This is a hybrid meeting open to the public.<\/li>\n
    • December 8-9, 2026: <\/strong>HHS announced a meeting of PTAC. This is a hybrid meeting open to the public.<\/li>\n
    • January 16, 2027:<\/strong> HHS announced a meeting of the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria. This is a virtual meeting open to the public.<\/li>\n<\/ul>\n

      Reports, Studies & Analyses<\/h2>\n
        \n
      • On May 28, 2026, the Congressional Research Service (CRS) released a report entitled, FDA Regulation of Medication Abortion: Recent Legal Developments<\/em>. CRS found that some of the more prominent pending cases regarding regulation of medication abortion drugs involve claims that FDA\u2019s actions relating to the medication abortion drug, mifepristone, are unlawful. Plaintiffs in these cases seek changes to current federal prescribing and dispensing requirements. The claims in these cases vary widely. While some suits allege that FDA improperly considered the risks of mifepristone and unlawfully approved or set controls for the drug that are too relaxed, others contend that FDA inappropriately limited access to mifepristone and that the drug should be easier to obtain. In Louisiana v. FDA<\/em>, the U.S. Court of Appeals for the Fifth Circuit granted a motion to stay FDA’s current mifepristone requirements, which allow patients to obtain the drug via remote prescribing and dispensing, but the U.S. Supreme Court paused this stay. As the litigation continues, remote prescribing and dispensing of mifepristone remains available. CRS notes that any forthcoming administrative changes to the mifepristone Risk Evaluation Management Strategy (REMS) may alter the procedural posture of the ongoing cases or spur new litigation. Lastly, CRS notes that Congress may choose to amend federal law to specify the conditions in which these products are available to patients, or to clarify the degree to which federal regulation of medication abortion drugs preempts state measures inconsistent with federal policy.<\/li>\n
      • On May 28, 2026, KFF released a report entitled, Medicare Advantage Out-of-Pocket Limits: Variation and Trends<\/em>. This report analyzes out-of-pocket limits in Medicare Advantage (MA) plans in 2026, including variation by plan type, the distribution of enrollees facing different out-of-pocket limits, and trends over time. According to KFF, in 2026, the average enrollment-weighted out-of-pocket limit for MA enrollees was $5,421 for in-network services alone and $9,825 for in-network and out-of-network services combined. Further, just over one in 10 MA enrollees (13 percent, or 2.8 million people) were in plans with limits of $3,000 or less for in-network services in 2026. More than two-thirds (68 percent) were in plans with limits above $3,000 and up to $7,000, and about one in five (19 percent) were in plans with limits above $7,000. Additionally, about one in 10 (9 percent, or 1.8 million) MA enrollees were in plans with the maximum out-of-pocket limit for in-network services ($9,250). According to the report, the maximum allowable out-of-pocket cap has generally increased over time, consistent with projected beneficiary out-of-pocket spending in Medicare fee-for-service (FFS), which CMS uses to calculate maximum out-of-pocket limits in MA.<\/li>\n<\/ul>\n

        Other Health Policy News<\/h2>\n
          \n
        • On May 27, 2026, the U.S. District Court for the Southern District of Georgia ruled that 20 measures CMS uses to assess quality are improper and ordered CMS to recalculate Clover Health\u2019s 2026 scores. The decision could have industrywide implications, as CMS applied those metrics to every MA carrier.\n

          Under the Star Ratings program, CMS rates MA insurers on approximately 40 quality metrics related to plan administration, health outcomes, and customer experience. CMS awards each contract a rating of up to five stars, and insurers that earn at least four stars receive a 5 percent bonus payment.<\/p>\n

          Clover Health filed suit in November, alleging an estimated $120 million in missed bonus payments as a result of its rating decrease from 4 to 3.5 stars for its preferred provider organization (PPO) plan, which covers nearly all its MA population. The company\u2019s health maintenance organization (HMO) plan received a 4-star rating for 2026 and was not part of the litigation.<\/p>\n

          The court found that CMS improperly relied on 10 measures, including medication adherence measures and call center data, that were not drawn from data collected under its authority governing MA quality improvement programs. The judge also deemed the calculation \u201cprocedurally invalid\u201d, finding that CMS failed to properly engage in the notice-and-comment process for the remaining 10 measures.<\/p>\n

          CMS filed a motion for reconsideration with the court on May 28, arguing that the court improperly declined to consider CMS\u2019s reply to the plaintiff\u2019s request for a summary judgment because the court mistakenly thought CMS\u2019s reply was filed after the deadline.<\/p>\n

          The opinion from the U.S. District Court for the Southern District of Georgia is available here. The motion for reconsideration is available here.<\/p>\n<\/li>\n

        • On May 28, 2026, CMS released a final rule entitled, Medicare Program; Alternative Payment Model Updates and the Increasing Organ Transplant Access (IOTA) Model<\/em>. This final rule finalizes updates and revisions to the IOTA Model for PY 2, which will begin on July 1, 2026, and future PYs, in response to improvement opportunities that arose during implementation of the 2024 Medicare Program; Alternative Payment Model Updates and the Increasing Organ Transplant Access (IOTA) Model<\/em> final rule and to better align the model with new administration priorities. The IOTA Model is a 6-year mandatory alternative payment model that began on July 1, 2025, and will end on June 30, 2031. The model is aimed at kidney transplant hospitals with the goal of increasing the number of kidney transplants, improving quality, and improving patient experience during the transplant process.\n

          The final rule increases the low-volume threshold of participation from a minimum of 11 kidney transplants performed during each of the baseline years to 15 and modifies the eligible kidney transplant hospitals criteria to exclude military medical treatment facilities and Department of Veterans Affairs (VA) medical facilities. Additionally, the final rule allows for the inclusion of MA patients in the definition of Medicare kidney transplants so that upside risk payments and downside risk payments are only based on kidney transplants for beneficiaries with Medicare FFS or MA as a primary or secondary payer while maintaining maximum upside risk payment at $15,000. CMS also updated its risk-adjustment methodology for the composite graft survival rate.<\/p>\n

          Lastly, beginning in PY 3, participants must provide semi-annual notifications to Medicare beneficiaries who are active and have been on their waitlist for at least three years, detailing the number of and reasons for organ declinations made on their behalf, although patients retain the right to opt out of receiving these communications. Participants must notify Medicare beneficiary waitlist patients of status changes within 10 days of them becoming ineligible for organ offers (if not redundant with existing HHS guidance), providing the reason, reactivation information, and notifying the patient’s dialysis facility and nephrologist\/managing clinician when applicable.<\/p>\n

          The final rule can be found here. A fact sheet is available here.<\/p>\n<\/li>\n

        • On May 28, 2026, the Tri-Agencies and the Office of Personnel Management released final rules entitled, Federal Independent Dispute Resolution Operations<\/em>, which finalize updated standards for plans and issuers, providers, and certified IDR entities related to the Federal IDR process under the NSA. These final rules will require plans to use standardized claim adjustment and remittance codes to identify whether claims are subject to the NSA and Federal IDR process. Plans also must provide additional identifying and contact information with initial payments or denials. The Tri-Agencies note that these provisions are intended to reduce ambiguity and improve provider visibility into plan determinations and Qualifying Payment Amount (QPA)-related information.\n

          Furthermore, the final rules formalize use of the federal portal for open negotiation notices and responses and establishes additional documentation and timing requirements. The final rules also impose new timelines for eligibility determinations, create additional information-sharing requirements, and establish a federal payer registration process intended to improve identification of plans and enforcement oversight.<\/p>\n

          The Tri-Agencies also finalized broader flexibility for batching certain claims, including specialty-specific categories for anesthesiology, radiology, pathology and laboratory services, while imposing a 50-line-item cap per dispute. Lastly, the final rules finalized a $15 administrative fee per party per dispute (previously $115), reflecting concerns regarding accessibility and sustainability of the IDR process.<\/p>\n

          The final rules can be found here. A press release is available here. A fact sheet is available here.<\/p>\n<\/li>\n<\/ul>\n<\/div>\n

          [View source.]<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

          Below is Alston & Bird\u2019s Health Care Week in Review, which provides a synopsis of the latest news in health care regulations, notices, and guidance; federal legislation and congressional committee action; reports, studies, and analyses; and other health policy news. Highlight of the Week This week, the Tri-Agencies finalized updated standards for payers, providers, and […]<\/p>\n","protected":false},"author":1,"featured_media":4714,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[496,2303,2304,196,2593,1204,260,2476,192,2331,699,1087,2453,1850,3645,1709,2202,2294,695,3646,3644,1732,2232],"class_list":["post-4713","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog","tag-access","tag-alston","tag-bird","tag-care","tag-cms","tag-dispute","tag-federal","tag-final","tag-health","tag-idr","tag-increasing","tag-independent","tag-model","tag-operations","tag-organ","tag-release","tag-resolution","tag-review","tag-rule","tag-transplant","tag-triagencies","tag-updates","tag-week"],"_links":{"self":[{"href":"https:\/\/www.insuracarelife.com\/blog\/wp-json\/wp\/v2\/posts\/4713","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insuracarelife.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insuracarelife.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insuracarelife.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insuracarelife.com\/blog\/wp-json\/wp\/v2\/comments?post=4713"}],"version-history":[{"count":0,"href":"https:\/\/www.insuracarelife.com\/blog\/wp-json\/wp\/v2\/posts\/4713\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insuracarelife.com\/blog\/wp-json\/wp\/v2\/media\/4714"}],"wp:attachment":[{"href":"https:\/\/www.insuracarelife.com\/blog\/wp-json\/wp\/v2\/media?parent=4713"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insuracarelife.com\/blog\/wp-json\/wp\/v2\/categories?post=4713"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insuracarelife.com\/blog\/wp-json\/wp\/v2\/tags?post=4713"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}